Triple-negative breast cancer (TNBC) is a molecularly-defined subtype of breast cancer characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and HER2 expression. TNBC represents approximately 10-15% of breast cancers and is clinically aggressive with higher rates of recurrence and visceral/brain metastases. TNBC is molecularly heterogeneous, encompassing several intrinsic subtypes including basal-like, mesenchymal, and immunomodulatory. Treatment relies on chemotherapy and increasingly immunotherapy, as hormonal and HER2-targeted therapies are ineffective by definition.
Ask a research question about Triple-Negative Breast Cancer. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Triple-Negative Breast Cancer
creation_date: '2026-01-26T02:55:13Z'
description: >-
Triple-negative breast cancer (TNBC) is a molecularly-defined subtype of breast
cancer characterized by the absence of estrogen receptor (ER), progesterone
receptor (PR), and HER2 expression. TNBC represents approximately 10-15% of
breast cancers and is clinically aggressive with higher rates of recurrence
and visceral/brain metastases. TNBC is molecularly heterogeneous, encompassing
several intrinsic subtypes including basal-like, mesenchymal, and
immunomodulatory. Treatment relies on chemotherapy and increasingly immunotherapy,
as hormonal and HER2-targeted therapies are ineffective by definition.
categories:
- Molecularly-Defined Cancer
- Breast Cancer Subtype
- Solid Tumor
parents:
- breast carcinoma
has_subtypes:
- name: Basal-like TNBC
description: >-
The most common TNBC subtype (50-75%), characterized by expression of basal
cytokeratins (CK5/6, CK14, CK17), EGFR expression, high proliferation, and
frequent TP53 and BRCA1 mutations. Overlaps significantly with BRCA1-associated
breast cancer.
evidence:
- reference: PMID:21633166
reference_title: "Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies."
supports: SUPPORT
snippet: >-
BL1 and BL2 subtypes had higher expression of cell cycle and DNA damage
response genes, and representative cell lines preferentially responded to
cisplatin.
explanation: >-
The Lehmann et al. study identified basal-like subtypes (BL1 and BL2) with
high cell cycle and DNA damage response gene expression, consistent with
high proliferation and BRCA1 mutations.
- name: Mesenchymal TNBC
description: >-
Characterized by epithelial-mesenchymal transition features, enrichment in
cell motility and differentiation pathways. May respond to PI3K/mTOR inhibition.
evidence:
- reference: PMID:21633166
reference_title: "Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies."
supports: SUPPORT
snippet: >-
M and MSL subtypes were enriched in GE for epithelial-mesenchymal transition,
and growth factor pathways and cell models responded to NVP-BEZ235 (a PI3K/mTOR
inhibitor) and dasatinib (an abl/src inhibitor).
explanation: >-
The Lehmann et al. study confirmed mesenchymal subtypes are enriched for EMT
and growth factor pathways, responding to PI3K/mTOR inhibition.
- name: Luminal Androgen Receptor (LAR) TNBC
description: >-
Despite being ER/PR-negative, LAR tumors express androgen receptor and have
luminal gene expression patterns. May benefit from androgen receptor-targeted
therapy. Often have PIK3CA mutations.
evidence:
- reference: PMID:21633166
reference_title: "Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies."
supports: SUPPORT
snippet: >-
The LAR subtype includes patients with decreased relapse-free survival and
was characterized by androgen receptor (AR) signaling. LAR cell lines were
uniquely sensitive to bicalutamide (an AR antagonist).
explanation: >-
The Lehmann et al. study identified the LAR subtype characterized by AR
signaling and sensitivity to AR antagonists.
- name: Immunomodulatory TNBC
description: >-
Characterized by immune cell infiltration and immune checkpoint expression.
Best responders to immune checkpoint inhibitor therapy.
evidence:
- reference: PMID:21633166
reference_title: "Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies."
supports: SUPPORT
snippet: >-
Cluster analysis identified 6 TNBC subtypes displaying unique GE and
ontologies, including 2 basal-like (BL1 and BL2), an immunomodulatory (IM),
a mesenchymal (M), a mesenchymal stem-like (MSL), and a luminal androgen
receptor (LAR) subtype.
explanation: >-
The Lehmann et al. study identified the immunomodulatory (IM) subtype as
one of the six TNBC subtypes with unique gene expression profiles.
pathophysiology:
- name: Loss of Hormone Receptor Signaling
description: >-
TNBC lacks expression of estrogen receptor alpha (ESR1) and progesterone
receptor (PGR), eliminating the growth-promoting effects of estrogen signaling
that drive most breast cancers. This absence removes a key therapeutic target
but also indicates fundamentally different tumor biology.
evidence:
- reference: PMID:35987766
reference_title: "Triple negative breast cancer: Pitfalls and progress."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Triple negative breast cancer (TNBC) is characterized by the lack of
estrogen and progesterone receptor expression and lacks HER2 overexpression
or gene amplification.
explanation: >-
This review abstract defines TNBC by absent ER and PR expression with
absent HER2 overexpression, directly supporting loss of hormone receptor
signaling as a defining mechanistic feature.
biological_processes:
- preferred_term: estrogen receptor signaling pathway
modifier: ABSENT
term:
id: GO:0030520
label: estrogen receptor signaling pathway
notes: >-
The receptor absent here is the ESR1 product, but the mechanism is loss of
expression rather than an alteration in the gene: ESR1 is not among this
entry's causal genes and no source cited here reports an ESR1 variant in
triple-negative disease. Promoter hypermethylation is one documented route
to that loss and is reported in a minority of triple-negative tumors in a
cohort of Indian women (PMID:22362381), in whom ER-negative and
triple-negative disease is itself more common, which does not support a
gene-level claim for the subtype as a whole. The absence is therefore carried by the ABSENT modifier on the
pathway term and no receptor gene is bound on this node.
downstream:
- target: Alternative Oncogenic Pathways
description: Other signaling pathways drive proliferation in absence of ER
- name: Alternative Oncogenic Pathways
description: >-
In the absence of hormone receptor signaling, TNBC is driven by alternative
oncogenic pathways including EGFR signaling, PI3K-AKT-mTOR activation, and
Wnt/beta-catenin signaling. Many TNBCs have TP53 mutations eliminating this
tumor suppressor checkpoint.
biological_processes:
- preferred_term: epidermal growth factor receptor signaling pathway
modifier: INCREASED
term:
id: GO:0007173
label: epidermal growth factor receptor signaling pathway
- preferred_term: phosphatidylinositol 3-kinase signaling
modifier: INCREASED
term:
id: GO:0043491
label: phosphatidylinositol 3-kinase/protein kinase B signal transduction
downstream:
- target: Aggressive Tumor Behavior
description: Multiple activated pathways drive aggressive phenotype
- name: DNA Repair Deficiency
description: >-
A significant subset of TNBC (~20%) harbors germline or somatic BRCA1/2
mutations resulting in homologous recombination deficiency. This creates
sensitivity to platinum chemotherapy and PARP inhibitors through synthetic
lethality.
biological_processes:
- preferred_term: homologous recombination
modifier: DECREASED
term:
id: GO:0035825
label: homologous recombination
evidence:
- reference: PMID:33475295
reference_title: "PARP Inhibitors in Triple-Negative Breast Cancer Including Those With BRCA Mutations."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
PARP inhibition causes synthetic lethality in breast cancers associated
with germline BRCA1 and BRCA2 mutations and is routinely used in clinical
practice for metastatic breast cancer.
explanation: >-
Supports the therapeutic consequence of homologous-recombination deficiency
in BRCA-mutated breast cancer. It does not support the "~20% of TNBC"
prevalence figure in the node description, which remains uncited.
downstream:
- target: Genomic Instability
description: DNA repair defects lead to mutation accumulation
- name: Genomic Instability
conforms_to: "genome_instability_mutation#Mutator Phenotype and Chromosomal Instability"
description: >-
Loss of high-fidelity double-strand-break repair, compounded by near-universal
TP53 inactivation, produces a mutator phenotype and pervasive chromosomal
instability. This is the enabling characteristic that supplies the driver
lesions feeding the alternative oncogenic pathways and aggressive behavior of
TNBC.
biological_processes:
- preferred_term: DNA damage response
modifier: ABNORMAL
term:
id: GO:0006974
label: DNA damage response
- preferred_term: chromosome segregation
modifier: ABNORMAL
term:
id: GO:0007059
label: chromosome segregation
evidence:
- reference: PMID:31045815
reference_title: "Association of p53 expression with poor prognosis in patients with triple-negative breast invasive ductal carcinoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "TP53 gene is mutated in approximately 80% of triple-negative breast cancer (TNBC)."
explanation: >-
Supports near-universal loss of the TP53 checkpoint in TNBC, the principal
permissive lesion for the mutator/chromosomal-instability phenotype. Direct
TNBC genomic-scarring evidence is still needed.
downstream:
- target: Aggressive Tumor Behavior
description: >-
Accumulated driver lesions and chromosomal instability fuel clonal evolution
and the aggressive clinical course.
- name: Macrophage-Mediated Immune Suppression
description: >-
The TNBC microenvironment is immunosuppressive, with pro-inflammatory M1
macrophage polarization suppressed. Apolipoprotein C-II (APOC2) is upregulated
in TNBC tissue and inversely correlates with M1 macrophage infiltration;
overexpressing it in tumor cells suppresses M1 polarization and promotes tumor
growth, so the effect on macrophages is tumor-cell-extrinsic. KLHL1 (a
Cullin3-RING E3 ubiquitin ligase substrate adaptor) degrades APOC2 via the
ubiquitin-proteasome pathway and reverses this immunosuppressive phenotype by
restoring M1 polarization.
notes: >-
Scoped to what PMID:42600954 measures. That study reports M1 infiltration and
M1 polarization only and never assays M2 markers, so no M2-skewing claim is
made here even though M2 polarization in the TNBC microenvironment is
well described elsewhere; curating it needs its own reference.
biological_processes:
- preferred_term: inflammatory response
modifier: DECREASED
term:
id: GO:0006954
label: inflammatory response
- preferred_term: M1 macrophage polarization
modifier: DECREASED
term:
id: GO:0002281
label: macrophage activation involved in immune response
cell_types:
- preferred_term: M1 macrophage
term:
id: CL:0000863
label: M1 macrophage
evidence:
- reference: PMID:42600954
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "APOC2 was upregulated in TNBC tissues and was negatively correlated with M1 macrophage infiltration."
explanation: >-
Establishes APOC2 upregulation in TNBC as negatively correlating with
anti-tumor M1 macrophage infiltration. This is the tissue-expression arm
of the study, stated before any cell-line or xenograft work.
- reference: PMID:42600954
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "KLHL1 promoted APOC2 protein degradation through the ubiquitin-proteasome pathway, thereby enhancing M1 macrophage polarization and suppressing the malignant behavior of tumor cells."
explanation: >-
KLHL1-mediated APOC2 degradation enhances M1 macrophage polarization,
restoring anti-tumor immunity. The quoted mechanism follows the
co-immunoprecipitation and 4T1 cell experiments, so it is cell-based.
- reference: PMID:42600954
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "in vivo xenograft experiments demonstrated that APOC2 reduced M1 macrophage polarization and increased tumor weight and volume, whereas KLHL1 overexpression counteracted the oncogenic effects of APOC2"
explanation: >-
Confirms the APOC2-driven suppression of M1 polarization, and its
reversal by KLHL1, in a tumor-bearing animal rather than in culture.
downstream:
- target: Aggressive Tumor Behavior
description: Suppression of M1 polarization promotes tumor progression.
evidence:
- reference: PMID:42600954
reference_title: KLHL1 suppresses triple-negative breast cancer progression by promoting M1 macrophage polarization via APOC2 degradation.
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "in vivo xenograft experiments demonstrated that APOC2 reduced M1 macrophage polarization and increased tumor weight and volume, whereas KLHL1 overexpression counteracted the oncogenic effects of APOC2"
explanation: >-
Evidences the edge rather than either node it joins: the same manipulation
that reduces M1 polarization increases tumor weight and volume, and
reversing it reverses both.
- target: Intratumoral CXCL9 Deficiency
causal_link_type: DIRECT
description: >-
Macrophages are a principal source of the CD8-recruiting chemokine CXCL9, so
an immunosuppressed macrophage compartment leaves the tumor short of it.
evidence:
- reference: PMID:42168200
reference_title: Macrophage ALDH2 drives immunotherapy resistance by silencing CXCL9 through metabolic-epigenetic crosstalk.
supports: SUPPORT
directness: DIRECT
evidence_source: MODEL_ORGANISM
snippet: "Myeloid-restricted ALDH2 ablation converts TAMs from a pro-tumorigenic phenotype to immunostimulatory regulators, concomitantly amplifying CD8+ T cell infiltration and cytotoxicity to improve ICB responsiveness"
explanation: >-
Reversing the macrophage immunosuppressive phenotype restores the CXCL9
output and the CD8 infiltration that depends on it, which is this edge
read in the rescue direction.
- name: Intratumoral CXCL9 Deficiency
biological_scale: TISSUE
description: >-
CXCL9 is the dominant CXCR3 ligand recruiting cytotoxic T lymphocytes into
solid tumors, and tumor-associated macrophages are a principal source of it.
Where the macrophage compartment is immunosuppressed, intratumoral CXCL9 is
low, and in breast cancer its expression tracks with both immune infiltration
and survival. Restoring it is sufficient to pull CTLs back into the tumor,
which is what makes the deficiency causal rather than merely correlated.
notes: >-
The human evidence here is expression-correlative (TCGA-BRCA and the Kim
cohorts) and the interventional evidence is from mouse models, so the node is
stated as a chemokine deficiency in the tumor microenvironment rather than as
a measured CXCL9 concentration in patient tissue. No study cited here reports
the latter.
cell_types:
- preferred_term: tumor-associated macrophage
term:
id: CL:0000235
label: macrophage
- preferred_term: TREM2-positive tumor-associated macrophage
term:
id: CL:4047053
label: TREM2-positive macrophage
biological_processes:
- preferred_term: CXCL9-CXCR3 chemokine signaling
modifier: DECREASED
term:
id: GO:0070098
label: chemokine-mediated signaling pathway
genes:
- preferred_term: CXCL9
term:
id: hgnc:7098
label: CXCL9
- preferred_term: TREM2
term:
id: hgnc:17761
label: TREM2
evidence:
- reference: PMID:41588017
reference_title: Co-delivery of chemokine CXCL9 and costimulatory ligand TNFSF9 by mesenchymal stem cells reprograms the immune microenvironment for triple-negative breast cancer.
supports: SUPPORT
directness: INDIRECT
evidence_source: HUMAN_CLINICAL
snippet: "analysis of human datasets (TCGA-BRCA and Kim cohorts) revealed that tumor necrosis factor superfamily member 9 (TNFSF9) and C-X-C motif chemokine ligand (CXCL9) expressions correlate with improved prognosis and enhanced immune cell infiltration"
explanation: >-
Human breast-cancer cohorts tie CXCL9 expression to immune infiltration and
outcome. Graded INDIRECT because a positive correlation between higher CXCL9
and better infiltration is the claim read backwards; it establishes the axis,
not that low CXCL9 is what excludes the T cells.
- reference: PMID:42726873
reference_title: Targeting tumor-associated macrophages using mRNA lipid nanoparticles for cytotoxic T lymphocyte-mediated cancer immunotherapy.
supports: SUPPORT
directness: DIRECT
quote_role: BACKGROUND
evidence_source: OTHER
snippet: "targets the protein triggering receptor expressed on myeloid cells 2 (TREM2) expressed by tumor-associated macrophages (TAMs)"
explanation: >-
Establishes TREM2 as a surface marker of the tumor-associated macrophages
this node binds, which is what the CL:4047053 binding asserts. The quoted
sentence states the premise the paper's targeting strategy rests on, not a
result it produced, so quote_role is BACKGROUND. The paper's own
experiments are murine, but this sentence reports no experiment at all,
which is why evidence_source is OTHER rather than MODEL_ORGANISM.
downstream:
- target: Cytotoxic T Lymphocyte Exclusion
causal_link_type: DIRECT
description: >-
Too little CXCL9 in the tumor means too little CXCR3-driven chemotaxis of
CD8-positive T cells across the tumor margin.
evidence:
- reference: PMID:42168200
reference_title: Macrophage ALDH2 drives immunotherapy resistance by silencing CXCL9 through metabolic-epigenetic crosstalk.
supports: SUPPORT
directness: DIRECT
evidence_source: MODEL_ORGANISM
snippet: "Subsequent CXCL9 derepression in TAMs facilitates persistent CD8+ T cell infiltration and enhances their cytotoxic effector functions"
explanation: >-
States the edge itself: relieving the block on macrophage CXCL9 is what
produces CD8 infiltration, so the deficiency is what withholds it.
- name: Cytotoxic T Lymphocyte Exclusion
biological_scale: TISSUE
description: >-
TNBC tumors are poorly infiltrated by CD8-positive cytotoxic T lymphocytes,
which is the proximate reason immune checkpoint blockade benefits only a
minority of patients: a drug that releases a brake on T cells does little
where the T cells are not present. Supplying CXCL9 reverses the exclusion in
model systems.
cell_types:
- preferred_term: CD8-positive cytotoxic T lymphocyte
term:
id: CL:0000625
label: CD8-positive, alpha-beta T cell
biological_processes:
- preferred_term: T cell chemotaxis into the tumor
modifier: DECREASED
term:
id: GO:0010818
label: T cell chemotaxis
evidence:
- reference: PMID:41588017
reference_title: Co-delivery of chemokine CXCL9 and costimulatory ligand TNFSF9 by mesenchymal stem cells reprograms the immune microenvironment for triple-negative breast cancer.
supports: SUPPORT
directness: DIRECT
quote_role: BACKGROUND
evidence_source: OTHER
snippet: "Due to limited tumor immune infiltration in TNBC, the effectiveness of immunotherapy is constrained"
explanation: >-
States the node for TNBC specifically, and the consequence that makes it
matter clinically. quote_role BACKGROUND records that the sentence is the
paper's framing rather than a result it reports, and evidence_source is
OTHER because the sentence itself reports no study.
- reference: PMID:42726873
reference_title: Targeting tumor-associated macrophages using mRNA lipid nanoparticles for cytotoxic T lymphocyte-mediated cancer immunotherapy.
supports: SUPPORT
directness: INDIRECT
evidence_source: MODEL_ORGANISM
snippet: "codelivery of a Toll-like receptor agonist and CXCL9-encoding mRNA encapsulated in our Ab-LNP successfully ameliorates immunosuppression and improves tumor infiltration and activity of CTLs"
explanation: >-
A therapeutic rescue cited as validation of the mechanism it targets:
restoring CXCL9 to TREM2-positive macrophages improves CTL infiltration, so
the exclusion is CXCL9-dependent and reversible. INDIRECT because the claim
follows from the intervention working rather than being asserted, and the
system is an orthotopic mouse model.
downstream:
- target: Aggressive Tumor Behavior
causal_link_type: DIRECT
description: >-
Without cytotoxic T cells in the tumor, immune control of outgrowth is lost.
evidence:
- reference: PMID:41588017
reference_title: Co-delivery of chemokine CXCL9 and costimulatory ligand TNFSF9 by mesenchymal stem cells reprograms the immune microenvironment for triple-negative breast cancer.
supports: SUPPORT
directness: INDIRECT
evidence_source: MODEL_ORGANISM
snippet: "effectively suppresses TNBC growth by reprogramming the intra-tumoral immune landscape"
explanation: >-
Reversing the infiltration deficit suppresses tumor growth, which is this
edge read in the rescue direction. INDIRECT because the growth effect is
attributed to the immune landscape as a whole rather than to CD8
infiltration in isolation.
- name: Aggressive Tumor Behavior
description: >-
TNBC is characterized by high proliferation rates, early metastasis (especially
to viscera and brain), and shorter time to recurrence compared to other breast
cancer subtypes. The aggressive biology reflects activation of multiple
oncogenic pathways and loss of tumor suppressors.
evidence:
- reference: PMID:35987766
reference_title: "Triple negative breast cancer: Pitfalls and progress."
supports: SUPPORT
snippet: "It accounts for 10-15% of incident breast cancers and carries the worst prognosis."
explanation: "Abstract states TNBC carries the worst prognosis, supporting aggressive behavior."
biological_processes:
- preferred_term: cell population proliferation
modifier: INCREASED
term:
id: GO:0008283
label: cell population proliferation
histopathology:
- name: Invasive Ductal Carcinoma
finding_term:
preferred_term: Invasive Breast Carcinoma of No Special Type
term:
id: NCIT:C4194
label: Invasive Breast Carcinoma of No Special Type
frequency: VERY_FREQUENT
description: Invasive ductal carcinoma is the most common type of breast cancer.
evidence:
- reference: PMID:39806949
reference_title: "An Overview of Invasive Ductal Carcinoma (IDC) in Women's Breast Cancer."
supports: SUPPORT
snippet: "Invasive ductal carcinoma (IDC) is the most common type of breast cancer,"
explanation: Abstract states that invasive ductal carcinoma is the most common breast cancer type.
phenotypes:
- category: Neoplastic
name: Breast Carcinoma
frequency: OBLIGATE
diagnostic: true
description: >-
Triple-negative breast cancers are typically high-grade invasive ductal
carcinomas with high mitotic rates. Medullary and metaplastic histologies
are enriched in the TNBC population.
phenotype_term:
preferred_term: Breast carcinoma
term:
id: HP:0003002
label: Breast carcinoma
- category: Clinical
name: Early Visceral Metastases
frequency: FREQUENT
description: >-
TNBC has a predilection for visceral metastases (lung, liver) and brain
metastases, occurring earlier and more frequently than in ER+ breast cancer.
notes: >-
HPO has no generic metastasis term, so this is bound to the coarse parent
HP:0002664 Neoplasm. The binding does not convey the metastatic or visceral
specificity described here.
phenotype_term:
preferred_term: Neoplasm
term:
id: HP:0002664
label: Neoplasm
- category: Molecular
name: Triple-Negative Phenotype
frequency: OBLIGATE
diagnostic: true
description: >-
Defining feature is absence of ER (<1%), PR (<1%), and HER2 (IHC 0-1+ or
FISH non-amplified). This is a diagnosis of exclusion from other breast
cancer subtypes. Note: this is a receptor-status molecular classification,
not an HPO-modelled clinical abnormality; the HP:0002664 Neoplasm binding
below is a placeholder and does not represent the triple-negative state.
evidence:
- reference: PMID:35987766
reference_title: "Triple negative breast cancer: Pitfalls and progress."
supports: SUPPORT
evidence_source: OTHER
snippet: "Triple negative breast cancer (TNBC) is characterized by the lack of estrogen and progesterone receptor expression and lacks HER2 overexpression or gene amplification."
explanation: "Abstract defines TNBC by lack of ER/PR and HER2, matching the diagnostic phenotype."
phenotype_term:
preferred_term: Neoplasm
term:
id: HP:0002664
label: Neoplasm
biochemical:
- name: Hormone Receptor and HER2 Testing
notes: >-
Diagnosis requires testing for ER, PR (by IHC), and HER2 (by IHC and/or FISH).
Triple-negative is defined as ER <1%, PR <1%, and HER2 0-1+ or non-amplified.
PD-L1 testing (CPS or SP142) is recommended for treatment selection.
- name: BRCA1/2 Testing
notes: >-
Germline BRCA1/2 testing is recommended for all TNBC patients given high
prevalence of mutations (~15-20%) and therapeutic implications (PARP inhibitors).
Somatic testing may identify additional HRD-positive tumors.
genetic:
- name: TP53
gene_term:
preferred_term: TP53
term:
id: hgnc:11998
label: TP53
association: Somatic Mutations
relationship_type: SOMATIC_DRIVER
variant_origin: SOMATIC
notes: >-
TP53 mutations occur in approximately 80% of TNBC, the highest rate among
breast cancer subtypes. Mutations are typically missense in the DNA-binding
domain or truncating mutations.
evidence:
- reference: PMID:31045815
reference_title: "Association of p53 expression with poor prognosis in patients with triple-negative breast invasive ductal carcinoma."
supports: SUPPORT
snippet: "TP53 gene is mutated in approximately 80% of triple-negative breast cancer (TNBC)."
explanation: "Abstract reports TP53 mutation frequency in TNBC, supporting this genetic association."
- name: BRCA1
gene_term:
preferred_term: BRCA1
term:
id: hgnc:1100
label: BRCA1
association: Germline and Somatic Mutations
relationship_type: RISK_FACTOR
variant_origin: GERMLINE_AND_SOMATIC
notes: >-
BRCA1 germline mutations are enriched in TNBC, occurring in 10-15% of cases.
BRCA1-associated breast cancers are predominantly triple-negative and basal-like.
Somatic BRCA1 mutations and promoter methylation also occur.
- name: PIK3CA
gene_term:
preferred_term: PIK3CA
term:
id: hgnc:8975
label: PIK3CA
association: Somatic Mutations
relationship_type: SOMATIC_DRIVER
variant_origin: SOMATIC
notes: >-
PIK3CA mutations occur in approximately 10-20% of TNBC, particularly in the
LAR subtype. May identify patients who benefit from PI3K inhibitors.
treatments:
- name: Neoadjuvant Chemotherapy
description: >-
Standard treatment includes anthracycline and taxane-based regimens given
before surgery. Pathologic complete response (pCR) rates are higher in TNBC
than other subtypes and strongly predict long-term outcomes.
treatment_term:
preferred_term: Neoadjuvant Chemotherapy
term:
id: NCIT:C213450
label: Neoadjuvant Chemotherapy
evidence:
- reference: PMID:32046998
reference_title: "Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis."
supports: SUPPORT
snippet: >-
Patients with a pCR after NAT had significantly better EFS (HR = 0.31; 95%
PI, 0.24-0.39), particularly for triple-negative (HR = 0.18; 95% PI,
0.10-0.31) and HER2+ (HR = 0.32; 95% PI, 0.21-0.47) disease.
explanation: >-
Meta-analysis confirms that achieving pCR after neoadjuvant therapy is
strongly associated with improved event-free survival, particularly for TNBC.
- name: Pembrolizumab Plus Chemotherapy
description: >-
PD-1 inhibitor pembrolizumab combined with chemotherapy improves outcomes
in early-stage and metastatic TNBC. KEYNOTE-522 established pembrolizumab
in the neoadjuvant/adjuvant setting regardless of PD-L1 status.
treatment_term:
preferred_term: immunotherapy
term:
id: NCIT:C15262
label: Immunotherapy
therapeutic_agent:
- preferred_term: pembrolizumab
term:
id: NCIT:C106432
label: Pembrolizumab
evidence:
- reference: PMID:32101663
reference_title: "Pembrolizumab for Early Triple-Negative Breast Cancer."
supports: SUPPORT
snippet: >-
Among patients with early triple-negative breast cancer, the percentage
with a pathological complete response was significantly higher among those
who received pembrolizumab plus neoadjuvant chemotherapy than among those
who received placebo plus neoadjuvant chemotherapy.
explanation: >-
KEYNOTE-522 demonstrated significantly higher pCR rates with pembrolizumab
plus chemotherapy versus chemotherapy alone in early TNBC.
- name: PARP Inhibitors
description: >-
Olaparib and talazoparib are approved for germline BRCA-mutated metastatic
TNBC. They exploit synthetic lethality in HRD-positive tumors unable to
repair DNA double-strand breaks.
treatment_term:
preferred_term: targeted therapy
term:
id: NCIT:C93352
label: Targeted Therapy
evidence:
- reference: PMID:33475295
reference_title: "PARP Inhibitors in Triple-Negative Breast Cancer Including Those With BRCA Mutations."
supports: SUPPORT
snippet: >-
PARP inhibition causes synthetic lethality in breast cancers associated
with germline BRCA1 and BRCA2 mutations and is routinely used in clinical
practice for metastatic breast cancer.
explanation: >-
Review confirms PARP inhibitors cause synthetic lethality in BRCA-mutated
breast cancers and are standard of care for metastatic disease.
- name: Sacituzumab Govitecan
description: >-
Antibody-drug conjugate targeting Trop-2 with an SN-38 payload. Approved
for previously treated metastatic TNBC with significant survival benefit
demonstrated in ASCENT trial.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: sacituzumab govitecan
term:
id: NCIT:C102783
label: Sacituzumab Govitecan
evidence:
- reference: PMID:33882206
reference_title: "Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer."
supports: SUPPORT
snippet: >-
Progression-free and overall survival were significantly longer with
sacituzumab govitecan than with single-agent chemotherapy among patients
with metastatic triple-negative breast cancer.
explanation: >-
ASCENT trial demonstrated significant PFS and OS benefit with sacituzumab
govitecan versus chemotherapy in metastatic TNBC.
- name: Platinum Chemotherapy
description: >-
Carboplatin improves pCR rates in neoadjuvant therapy, particularly in
BRCA-mutated or HRD-positive TNBC. Used in combination with taxanes.
treatment_term:
preferred_term: chemotherapy
term:
id: NCIT:C15632
label: Chemotherapy
therapeutic_agent:
- preferred_term: carboplatin
term:
id: CHEBI:31355
label: carboplatin
evidence:
- reference: PMID:21633166
reference_title: "Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies."
supports: SUPPORT
snippet: >-
BL1 and BL2 subtypes had higher expression of cell cycle and DNA damage
response genes, and representative cell lines preferentially responded to
cisplatin.
explanation: >-
Basal-like TNBC subtypes with DNA damage response gene expression
preferentially respond to platinum chemotherapy.
disease_term:
preferred_term: triple-negative breast carcinoma
term:
id: MONDO:0005494
label: triple-negative breast carcinoma
mappings:
mondo_mappings:
- term:
id: MONDO:0005494
label: triple-negative breast carcinoma
mapping_predicate: skos:exactMatch
mapping_source: MONDO
mapping_justification: MONDO provides an exact disease term for triple-negative breast carcinoma.
classifications:
icdo_morphology:
classification_value: Adenocarcinoma
harrisons_chapter:
- classification_value: ONCOLOGY_HEMATOLOGY
references:
- reference: DOI:10.2147/bctt.s516542
title: 'Diagnosis, Prognosis, and Treatment of Triple-Negative Breast Cancer: A Review'
found_in:
- Triple_Negative_Breast_Cancer-deep-research-falcon.md
findings:
- statement: TNBC is defined by absence of ER, PR, and HER2 and remains clinically aggressive despite growing therapeutic options.
supporting_text: 'Diagnosis, Prognosis, and Treatment of Triple-Negative Breast Cancer: A Review'
- reference: DOI:10.3389/fonc.2024.1405491
title: 'Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies'
found_in:
- Triple_Negative_Breast_Cancer-deep-research-falcon.md
findings:
- statement: Contemporary TNBC management is increasingly shaped by immunotherapy, antibody-drug conjugates, and molecular stratification, but heterogeneity remains a central obstacle.
supporting_text: 'Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies'
- reference: DOI:10.3390/cancers17020228
title: Triple-Negative Breast Cancer Progression and Drug Resistance in the Context of Epithelial–Mesenchymal Transition
found_in:
- Triple_Negative_Breast_Cancer-deep-research-falcon.md
findings:
- statement: EMT-associated plasticity is a major contributor to TNBC progression, metastatic behavior, and therapy resistance.
supporting_text: 'Triple-Negative Breast Cancer Progression and Drug Resistance in the Context of Epithelial–Mesenchymal Transition'
- reference: DOI:10.53022/oarjbp.2024.10.2.0013
title: 'Triple Negative Breast Cancer (TNBC): Signalling pathways-Role of plant-based inhibitors'
found_in:
- Triple_Negative_Breast_Cancer-deep-research-falcon.md
findings:
- statement: Multiple signaling pathways remain mechanistically relevant in TNBC and motivate continued pathway-directed therapeutic exploration.
supporting_text: 'Triple Negative Breast Cancer (TNBC): Signalling pathways-Role of plant-based inhibitors'
datasets:
- accession: ega:EGAS00001003196
title: Exome-sequencing of paired docetaxel sensitive and resistant triple-negative breast cancer
description: Taxane-based regimens constitute the most common therapeutic option in patients with triple-negative breast cancer (TNBC). Resistance to treatment often arises although the molecular mechanisms responsible for this process are unknown. To unravel chemoresistance mechanisms, exome sequencing was performed on matched docetaxel sensitive and resistant TNBC patient-derived xenografts (PDX).
organism:
preferred_term: human
term:
id: NCBITaxon:9606
label: Homo sapiens
data_type: WES
notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Triple-Negative Breast Cancer"); description-level mentions were not accepted. EGA study_type: Exome Sequencing. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: ega:EGAS00001005892
title: Functional Mapping of AKT Signaling and Biomarkers of Response From the FAIRLANE Trial of Neoadjuvant Ipatasertib Plus Paclitaxel for Triple-Negative Breast Cancer
description: 'Purpose: Despite extensive genomic and transcriptomic profiling, it remains unknown how signaling pathways are differentially activated and how tumors are differentially sensitized to certain perturbations. Here, we aim to characterize AKT signaling activity and its association with other genomic or immunohistochemistry-based PI3K/AKT pathway biomarkers as well as the clinical activity of ipatasertib (AKT inhibitor) in the FAIRLANE trial. Experimental Design: In FAIRLANE, 151 patients with early triple-negative breast cancer were randomized 1:1 to receive paclitaxel with ipatasertib or placebo for 12 weeks prior to surgery.'
organism:
preferred_term: human
term:
id: NCBITaxon:9606
label: Homo sapiens
notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Triple-Negative Breast Cancer"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: ega:EGAS00001006079
title: Comprehensive Molecular Profiling Identifies Features of Disease Resistance to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
organism:
preferred_term: human
term:
id: NCBITaxon:9606
label: Homo sapiens
notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Triple-Negative Breast Cancer"); description-level mentions were not accepted. EGA study_type: Cancer Genomics. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: metabolomics_workbench:ST002408
title: Multi-omic Analysis of ClpP Activation in Triple-Negative Breast Cancer Cells
notes: Located via OmicsDI, which aggregates across omics repositories; this record comes from metabolomics_workbench. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Triple-Negative Breast Cancer"). Retrieved 2026-08-02.
- accession: metabolomics_workbench:ST002235
title: Application of Artificial Intelligence to Plasma Metabolomics Profiles to Predict Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
notes: Located via OmicsDI, which aggregates across omics repositories; this record comes from metabolomics_workbench. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Triple-Negative Breast Cancer"). Retrieved 2026-08-02.
- accession: metabolomics_workbench:ST002290
title: Metabolic impact of anticancer drugs Pd2Spermine and Cisplatin on the polar metabolome of brain from cell-derived xenograft mouse model of Triple-Negative Breast Cancer (part 1)
organism:
preferred_term: mouse
term:
id: NCBITaxon:10090
label: Mus musculus
data_type: METABOLOMICS
notes: Located via OmicsDI, which aggregates across omics repositories; this record comes from metabolomics_workbench. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Triple-Negative Breast Cancer"). Retrieved 2026-08-02.
Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.
Add the CXCL9 / cytotoxic-T-cell-exclusion arm downstream of macrophage immune suppression · 2026-09-13T06:50:16Z · View source
Extends the immune arm that PR #9543 opened. That PR added Macrophage-Mediated Immune Suppression (APOC2/KLHL1 -> M1 polarization) with a single bare edge to Aggressive Tumor Behavior; this adds the chain that connects macrophage immunosuppression to the entry's clinical problem, and evidences that bare edge. New nodes: Intratumoral CXCL9 Deficiency (TISSUE) and Cytotoxic T Lymphocyte Exclusion (TISSUE). Chain is Macrophage-Mediated Immune Suppression -> Intratumoral CXCL9 Deficiency -> Cytotoxic T Lymphocyte Exclusion -> Aggressive Tumor Behavior, with every edge carrying its own evidence rather than borrowing a node's. The entry previously had no immune pathophysiology beyond #9543's node, despite carrying an Immunomodulatory subtype and pembrolizumab as a treatment. The exclusion node is what makes that treatment's limited benefit legible: a drug that releases a brake on T cells does little where the T cells are not present. Three references, all newly cached. PMID:42726873 (Chen et al., Sci Adv 2026) is the TREM2-targeted mRNA-LNP paper the user supplied as a PDF; its PMID was confirmed against the DOI 10.1126/sciadv.aed9568 and first author before use, and only its abstract is cached, so the paper's human CXCL9/CD8A correlation (r=0.8191) and Kaplan-Meier data are deliberately not cited - they are in the Results, which the cache does not carry. PMID:42168200 supplies the macrophage-CXCL9-CD8 mechanism. PMID:41588017 supplies the human TNBC anchor (TCGA-BRCA and Kim cohorts) and the statement of limited infiltration in TNBC. Evidence grading is deliberately mixed and mostly not DIRECT: two items are therapeutic-rescue arguments (restoring CXCL9 improves CTL infiltration; reprogramming the immune landscape suppresses growth), which are INDIRECT per the directness rule - the claim follows from the intervention working rather than being asserted. The human cohort item is INDIRECT too, because a positive CXCL9-infiltration correlation is the deficiency claim read backwards. The TNBC infiltration statement is graded OTHER because it is that paper's background framing, not a result it reports. Ontology: CL:4047053 TREM2-positive macrophage and CL:0000625 CD8-positive, alpha-beta T cell were both looked up and label-verified against OLS before binding (CL:4047053 is new to the KB; its two cache rows are the only cache change). CL:0000235, GO:0070098, GO:0010818, hgnc:7098 and hgnc:17761 came from the committed caches. No CURIE was written from memory. Two deep-research reports exist for this entry and neither supports this axis: the committed openscientist report mentions CXCL9, TREM2, TAMs and CD8 zero times, and the falcon report states in its own limitations that myeloid and site-specific immunosuppression papers were not directly accessible in its evidence set. Sources were therefore found by PubMed search from the supplied paper outward, and that is recorded here rather than left implicit. The openscientist report also mislabels HP:0031416 and HP:0030075 and carries one unsupported quote (PMID:42373230); none of those were used. A notes field on the CXCL9 node records that the human evidence is expression-correlative and the interventional evidence is murine, so the node claims a microenvironmental deficiency rather than a measured patient-tissue CXCL9 concentration, which no cited study reports. Validated: just validate (schema + 27/27 snippets verified, up from 19/19), just validate-terms, just check-entity-refs, just check-causal-targets, just check-duplicate-keys, just check-qualifier-terms, plus the batched just validate-disorders and the whole-KB snippet gates.
Pathophysiology description (narrative) Triple-negative breast cancer is defined by the absence of ER, PR, and HER2 expression and accounts for about 15–20% of breast cancers. It is enriched in younger patients and in germline BRCA1 carriers, shows rapid early recurrence, and tends to metastasize viscerally. As a recent review summarized: “TNBC is characterized by its aggressive nature, limited treatment options, and poorer prognosis compared to other breast cancer subtypes,” with targeted strategies focusing on PARP inhibitors and immune checkpoint blockade but with persistent biomarker challenges (Frontiers in Oncology, 28 May 2024, https://doi.org/10.3389/fonc.2024.1405491). Mechanistically, TNBC exhibits profound genomic instability (frequent TP53 mutation; HRD in BRCA1/2 or broader HRR genes), PI3K/AKT/mTOR and EGFR pathway activation in subsets (including the luminal androgen receptor [LAR] subtype), epithelial–mesenchymal transition (EMT) and cancer stemness driving invasion and therapeutic resistance, and an often immunologically active yet variably suppressive tumor microenvironment (TME). Clinically, neoadjuvant chemotherapy remains foundational; however, residual disease after chemotherapy is common and portends high recurrence risk, underscoring the need to address EMT/stemness, DNA-repair defects, and immune evasion in combination regimens (Frontiers in Oncology, 2024; Breast Cancer: Targets and Therapy, 13 Mar 2025, https://doi.org/10.2147/bctt.s516542) (xiong2024advancementsandchallenges pages 1-2, jie2025diagnosisprognosisand pages 7-9).
Core Pathophysiology - Primary mechanisms - Homologous recombination deficiency (HRD) due to BRCA1/2 or broader HRR gene disruption creates genomic scarring, high mutation burden, and sensitivity to DNA-damaging agents (carboplatin) and PARP inhibition; HRD/TIL enrichment may also interface with ICI responsiveness (Breast Cancer: Targets and Therapy, 2025, https://doi.org/10.2147/bctt.s516542) (jie2025diagnosisprognosisand pages 7-9). - EMT and stemness: EMT programs downregulate E-cadherin and upregulate vimentin/N-cadherin, enabling motility, invasion, and resistance; EMT fosters cancer stem cell traits and post-chemotherapy minimal residual disease (Cancers, 12 Jan 2025, https://doi.org/10.3390/cancers17020228) (błaszczak2025triplenegativebreastcancer pages 2-4, błaszczak2025triplenegativebreastcancer pages 1-2). - PI3K/AKT/mTOR and EGFR signaling: frequently activated in TNBC and particularly in LAR or EGFR-high tumors, promoting proliferation, survival, and metabolic reprogramming (Breast Cancer: Targets and Therapy, 2025; review of EGFR ~70% positivity in TNBC and PI3K/AKT/mTOR involvement) (jie2025diagnosisprognosisand pages 7-9). - Tumor immune microenvironment: TNBCs often show higher TILs and PD-L1 expression, supporting chemo-ICI combinations; yet ICI monotherapy responses are modest, highlighting immune evasion and need for better biomarkers (Frontiers in Oncology, 2024) (xiong2024advancementsandchallenges pages 1-2). - Dysregulated molecular pathways - DNA repair: BRCA1/2-HRD axis (jie2025diagnosisprognosisand pages 7-9). - Growth/survival: EGFR→PI3K/AKT/mTOR; FGFR4 signaling altering lipid metabolism (jie2025diagnosisprognosisand pages 7-9). - EMT networks: canonical EMT TFs/signals (e.g., TGF-β, WNT/NOTCH/Hedgehog cross-talk) highlighted in EMT-focused reviews (błaszczak2025triplenegativebreastcancer pages 2-4, błaszczak2025triplenegativebreastcancer pages 1-2). - Cellular processes affected - Invasion/metastasis via EMT; therapy resistance linked to EMT/stemness; metabolic rewiring to support proliferation; context-dependent immune activation/suppression influencing NAC/ICI outcomes (błaszczak2025triplenegativebreastcancer pages 2-4, błaszczak2025triplenegativebreastcancer pages 1-2, xiong2024advancementsandchallenges pages 1-2, jie2025diagnosisprognosisand pages 7-9).
Key Molecular Players - Genes/Proteins (HGNC) - BRCA1 (HGNC:1100), BRCA2 (HGNC:1101): HRR; loss/HRD sensitizes to platinum/PARPi (jie2025diagnosisprognosisand pages 7-9). - TP53 (HGNC:11998): frequently mutated in TNBC; contributes to genomic instability (xiong2024advancementsandchallenges pages 1-2). - EGFR (HGNC:3236): overexpressed in ~70% of TNBC; activates PI3K/AKT/mTOR (jie2025diagnosisprognosisand pages 7-9). - FGFR4 (HGNC:3689): upregulated in TNBC; promotes proliferation/invasion and lipid metabolic changes (jie2025diagnosisprognosisand pages 7-9). - AR (HGNC:644): defines LAR subtype; therapeutic target under investigation (xiong2024advancementsandchallenges pages 1-2, yan2024understandingmechanismsof pages 30-35). - EMT markers/regulators: CDH1/E-cadherin (HGNC:1748) down; VIM (HGNC:12692) and CDH2/N-cadherin (HGNC:1749) up (błaszczak2025triplenegativebreastcancer pages 2-4, błaszczak2025triplenegativebreastcancer pages 1-2). - Chemical Entities (ChEBI) - Carboplatin (CHEBI:31355): platinum agent; higher pCR in HRD-positive TNBC (jie2025diagnosisprognosisand pages 7-9). - PARP inhibitors (class; e.g., olaparib, CHEBI:89745): effective in gBRCA-mutant TNBC (xiong2024advancementsandchallenges pages 1-2, jie2025diagnosisprognosisand pages 7-9). - Immune checkpoint inhibitors (e.g., pembrolizumab): benefit in PD-L1–positive TNBC with chemotherapy (xiong2024advancementsandchallenges pages 1-2). - Cell Types (CL) - Malignant basal-like epithelial cells (CL:0000066 derivative) exhibiting EMT/stemness (błaszczak2025triplenegativebreastcancer pages 2-4, błaszczak2025triplenegativebreastcancer pages 1-2). - Tumor-infiltrating lymphocytes (T cells; CL:0000084) variably abundant (xiong2024advancementsandchallenges pages 1-2). - Myeloid cells/macrophages (CL:0000235) and CAFs (CL:0000635) implicated in TME remodeling (overview) (xiong2024advancementsandchallenges pages 1-2). - Anatomical Locations (UBERON) - Mammary gland (UBERON:0001911); propensity for visceral metastases (lung UBERON:0002048; liver UBERON:0002107; brain UBERON:0000955) (xiong2024advancementsandchallenges pages 1-2).
Biological Processes (GO) disrupted - DNA repair via homologous recombination (GO:0000724) (jie2025diagnosisprognosisand pages 7-9). - Signal transduction via EGFR/PI3K/AKT (GO:0007173; GO:0043491; GO:0038083) (jie2025diagnosisprognosisand pages 7-9). - Epithelial to mesenchymal transition (GO:0001837) and regulation of cell migration (GO:0030334) (błaszczak2025triplenegativebreastcancer pages 2-4, błaszczak2025triplenegativebreastcancer pages 1-2). - Regulation of apoptotic process (GO:0042981) and cell cycle (GO:0051726) downstream of PI3K/AKT/EGFR (jie2025diagnosisprognosisand pages 7-9). - Immune response (GO:0006955), T cell activation (GO:0042110), and negative regulation within TME (overview) (xiong2024advancementsandchallenges pages 1-2).
Cellular Components (GO) implicated - Nucleus (GO:0005634) and DNA repair foci (GO:0035861) for HRR (jie2025diagnosisprognosisand pages 7-9). - Plasma membrane (GO:0005886) for EGFR/FGFR and AR (jie2025diagnosisprognosisand pages 7-9, xiong2024advancementsandchallenges pages 1-2). - Adherens junction (GO:0005912)/cell-cell junctions affected in EMT (błaszczak2025triplenegativebreastcancer pages 2-4, błaszczak2025triplenegativebreastcancer pages 1-2). - Extracellular space (GO:0005615)/ECM (GO:0031012) in invasion and CAF remodeling (overview) (xiong2024advancementsandchallenges pages 1-2).
Disease Progression (sequence) 1) Initiation: HRD/TP53 mutation and basal-like lineage programs drive genomic instability and rapid proliferation (xiong2024advancementsandchallenges pages 1-2, jie2025diagnosisprognosisand pages 7-9). 2) Local invasion: EMT program reduces E-cadherin and increases mesenchymal proteins, enabling dissemination; EGFR/PI3K signaling supports motility and survival (błaszczak2025triplenegativebreastcancer pages 2-4, błaszczak2025triplenegativebreastcancer pages 1-2, jie2025diagnosisprognosisand pages 7-9). 3) Systemic metastasis: preferential early visceral spread; immune contexture variably hot/cold; subsets exhibit LAR signaling (xiong2024advancementsandchallenges pages 1-2). 4) Treatment response/resistance: NAC induces pCR in a subset; residual disease (RCB-II/III) common and at high recurrence risk; EMT/stemness and HRD status influence sensitivity to platinum/PARPi and to chemo-ICI combinations (błaszczak2025triplenegativebreastcancer pages 1-2, jie2025diagnosisprognosisand pages 7-9, xiong2024advancementsandchallenges pages 1-2).
Phenotypic Manifestations (HP terms) - High histologic grade and high proliferative index (Ki-67) (HP:0030079; HP:0030064) (błaszczak2025triplenegativebreastcancer pages 1-2). - Early visceral metastasis (HP:0002725 for abnormal immune response context; clinical pattern: lung/liver/brain spread) (xiong2024advancementsandchallenges pages 1-2). - Poor response durability to monotherapy ICI; improved with chemo-ICI in PD-L1+ disease (clinical phenotype) (xiong2024advancementsandchallenges pages 1-2).
Subtype and biomarker context - Transcriptomic TNBC subtypes include basal-like, immunomodulatory (IM), mesenchymal (M), and LAR; LAR tumors show AR signaling and often PI3K pathway dependence (Frontiers in Oncology, 2024; review of LAR subgroup) (xiong2024advancementsandchallenges pages 1-2, yan2024understandingmechanismsof pages 30-35). - PD-L1 and TILs are key immune biomarkers for ICI benefit; HRD/BRCA status informs platinum/PARPi sensitivity (xiong2024advancementsandchallenges pages 1-2, jie2025diagnosisprognosisand pages 7-9).
Current applications and real-world implementations - Neoadjuvant chemotherapy remains standard, with carboplatin often added in HRD-positive patients to raise pCR rates; “HRD positivity…was significantly associated with a greater pathological complete response (pCR) rate, especially in those treated with carboplatin-containing neoadjuvant regimens” (study summary in Breast Cancer: Targets and Therapy, 2025) (jie2025diagnosisprognosisand pages 7-9). - Chemo-ICI combinations (e.g., pembrolizumab plus taxane/anthracycline) improve outcomes in PD-L1–positive and early-stage settings; monotherapy ICI has modest response rates (Frontiers in Oncology, 2024) (xiong2024advancementsandchallenges pages 1-2). - Targeted strategies under study: EGFR/PI3K/AKT/mTOR inhibitors; AR antagonists for LAR; FGFR4 targeting under exploration (jie2025diagnosisprognosisand pages 7-9, xiong2024advancementsandchallenges pages 1-2).
Expert opinions and analysis (authoritative sources) - “TNBC… presents significant challenges… Targeted therapies, including PARP inhibitors, immune checkpoint inhibitors… hold promise… Challenges… include identifying novel targets, exploring combination therapies, and developing predictive biomarkers” (Frontiers in Oncology, 2024, https://doi.org/10.3389/fonc.2024.1405491) (xiong2024advancementsandchallenges pages 1-2). - EMT as a resistance driver: “Chemoresistance in TNBC is closely related to the epithelial–mesenchymal transition (EMT)… increasing metastatic potential and resistance to standard chemotherapeutic treatments” (Cancers, 2025, https://doi.org/10.3390/cancers17020228) (błaszczak2025triplenegativebreastcancer pages 2-4, błaszczak2025triplenegativebreastcancer pages 1-2). - Clinical course and need for precision: the 2025 clinical review emphasizes integrating biomarkers (BRCA/HRD, PD-L1) and subtyping (LAR/IM/M) to tailor therapy and monitor residual disease post-NAC (Breast Cancer: Targets and Therapy, 2025, https://doi.org/10.2147/bctt.s516542) (jie2025diagnosisprognosisand pages 7-9).
Relevant statistics and data (recent) - Proportion: TNBC represents approximately 15–20% of breast cancers; it is more common in younger and African American women and in BRCA1 mutation carriers (Frontiers in Oncology, 2024, 28 May 2024, https://doi.org/10.3389/fonc.2024.1405491) (xiong2024advancementsandchallenges pages 1-2). - Early recurrence/metastasis: TNBC shows earlier visceral relapse and poorer prognosis than other subtypes (Frontiers in Oncology, 2024) (xiong2024advancementsandchallenges pages 1-2). - Neoadjuvant outcomes and prognostics: Post-NAC residual cancer (RCB-II/III) carries a 40–80% recurrence risk; high Ki-67 associates with worse outcomes (Cancers, 12 Jan 2025, https://doi.org/10.3390/cancers17020228) (błaszczak2025triplenegativebreastcancer pages 1-2). - Survival benchmarks (clinical review synthesis): 5-year OS around 30–45% in high-risk TNBC cohorts; high risk of distant metastasis within 2 years (Breast Cancer: Targets and Therapy, 13 Mar 2025, https://doi.org/10.2147/bctt.s516542) (jie2025diagnosisprognosisand pages 7-9).
Gene/protein annotations with ontology terms (examples) - BRCA1 (HGNC:1100): DNA repair by homologous recombination (GO:0000724); nucleus (GO:0005634). Evidence: association with PARP/platinum sensitivity in TNBC review (jie2025diagnosisprognosisand pages 7-9). - BRCA2 (HGNC:1101): DNA repair by HR (GO:0000724); nucleus (GO:0005634). Evidence: as above (jie2025diagnosisprognosisand pages 7-9). - TP53 (HGNC:11998): DNA damage response (GO:0006974); regulation of cell cycle arrest (GO:0071156); nucleus (GO:0005634). Evidence: frequent TNBC mutation (xiong2024advancementsandchallenges pages 1-2). - EGFR (HGNC:3236): EGFR signaling (GO:0007173); plasma membrane (GO:0005886). Evidence: prevalent in TNBC, PI3K/AKT/mTOR activation (jie2025diagnosisprognosisand pages 7-9). - AR (HGNC:644): androgen receptor signaling pathway (GO:0030521); nucleus/cytosol (GO:0005634/GO:0005829). Evidence: LAR subtype biology (xiong2024advancementsandchallenges pages 1-2, yan2024understandingmechanismsof pages 30-35).
Phenotype associations (HP terms; examples) - HP:0030079 (High histologic grade); HP:0030064 (High Ki-67) linked to poor outcomes in TNBC (błaszczak2025triplenegativebreastcancer pages 1-2). - HP:0002715 (Recurrent infections/immune changes not directly applicable); clinically, PD-L1/TILs inform immunotherapy benefit (xiong2024advancementsandchallenges pages 1-2).
Cell type involvement (CL terms; examples) - CL:0000066 (epithelial cell) → malignant basal-like epithelium with EMT/stemness (błaszczak2025triplenegativebreastcancer pages 2-4, błaszczak2025triplenegativebreastcancer pages 1-2). - CL:0000084 (T cell), CL:0000235 (macrophage), CL:0000635 (fibroblast/CAF) shape TME (overview) (xiong2024advancementsandchallenges pages 1-2).
Anatomical locations (UBERON; examples) - UBERON:0001911 (mammary gland). Common metastatic sites: UBERON:0002048 (lung), UBERON:0002107 (liver), UBERON:0000955 (brain) (xiong2024advancementsandchallenges pages 1-2).
Chemical entities (ChEBI; examples) - CHEBI:31355 (carboplatin) for HRD+ NAC; class: PARP inhibitors (e.g., olaparib CHEBI:89745) for gBRCA+ disease (jie2025diagnosisprognosisand pages 7-9, xiong2024advancementsandchallenges pages 1-2).
Evidence items with PMIDs/DOIs and direct quotes - “TNBC… poses significant challenges… Targeted therapies, including PARP inhibitors, immune checkpoint inhibitors… hold promise… [but] challenges in identifying novel targets… and developing predictive biomarkers” (Frontiers in Oncology, 28 May 2024, https://doi.org/10.3389/fonc.2024.1405491) (xiong2024advancementsandchallenges pages 1-2). - “Chemoresistance in TNBC is closely related to the epithelial–mesenchymal transition (EMT)… increasing metastatic potential and resistance to standard chemotherapeutic treatments” (Cancers, 12 Jan 2025, https://doi.org/10.3390/cancers17020228) (błaszczak2025triplenegativebreastcancer pages 2-4, błaszczak2025triplenegativebreastcancer pages 1-2). - Clinical course and treatment implications summarized with biomarker-driven precision (Breast Cancer: Targets and Therapy, 13 Mar 2025, https://doi.org/10.2147/bctt.s516542) (jie2025diagnosisprognosisand pages 7-9).
Recent developments (2023–2024 priority) - Consolidation of chemo-ICI regimens in early/PD-L1+ TNBC and emphasis on multi-omic biomarker development (Frontiers in Oncology, 2024) (xiong2024advancementsandchallenges pages 1-2). - HRD-guided intensification with platinum in NAC and PARP in gBRCA settings; lipid-metabolic crosstalk via FGFR4 and EGFR-PI3K axis proposed as targets (Breast Cancer: Targets and Therapy, 2025, summarizing recent studies) (jie2025diagnosisprognosisand pages 7-9).
Limitations - High-resolution single-cell and spatial TME mapping, detailed myeloid/Treg/CAF programs, and site-specific (e.g., liver) immunosuppression mechanisms are active research areas; authoritative, very recent 2024–2025 primary single-cell papers exist but were not directly accessible in the present evidence set. The conclusions above therefore emphasize robust review-level evidence available here (xiong2024advancementsandchallenges pages 1-2, jie2025diagnosisprognosisand pages 7-9) and focused EMT content (błaszczak2025triplenegativebreastcancer pages 2-4, błaszczak2025triplenegativebreastcancer pages 1-2).
References (with URLs and dates) - Xiong N, Wu H, Yu Z. Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies. Frontiers in Oncology. 28 May 2024. https://doi.org/10.3389/fonc.2024.1405491 (xiong2024advancementsandchallenges pages 1-2). - Jie H, Ma W, Huang C. Diagnosis, Prognosis, and Treatment of Triple-Negative Breast Cancer: A Review. Breast Cancer: Targets and Therapy. 13 Mar 2025. https://doi.org/10.2147/bctt.s516542 (jie2025diagnosisprognosisand pages 7-9). - Błaszczak E, et al. Triple-Negative Breast Cancer Progression and Drug Resistance in the Context of EMT. Cancers. 12 Jan 2025. https://doi.org/10.3390/cancers17020228 (błaszczak2025triplenegativebreastcancer pages 2-4, błaszczak2025triplenegativebreastcancer pages 1-2). - Yan G. Understanding Mechanisms of Oncogenesis and Identifying Markers of Drug Resistance in TNBC. 2024 (overview text) (yan2024understandingmechanismsof pages 30-35). - Malabadi RB, et al. Triple Negative Breast Cancer (TNBC): Signalling pathways—Role of plant-based inhibitors. OARJBP. 16 Mar 2024. https://doi.org/10.53022/oarjbp.2024.10.2.0013 (malabadi2024triplenegativebreast pages 1-2).
References
(xiong2024advancementsandchallenges pages 1-2): Nating Xiong, Heming Wu, and Zhikang Yu. Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies. Frontiers in Oncology, May 2024. URL: https://doi.org/10.3389/fonc.2024.1405491, doi:10.3389/fonc.2024.1405491. This article has 146 citations and is from a poor quality or predatory journal.
(jie2025diagnosisprognosisand pages 7-9): Huan Jie, Wenhui Ma, and Cong Huang. Diagnosis, prognosis, and treatment of triple-negative breast cancer: a review. Breast Cancer : Targets and Therapy, 17:265-274, Mar 2025. URL: https://doi.org/10.2147/bctt.s516542, doi:10.2147/bctt.s516542. This article has 27 citations.
(błaszczak2025triplenegativebreastcancer pages 2-4): Ewa Błaszczak, Paulina Miziak, Adrian Odrzywolski, Marzena Baran, Ewelina Gumbarewicz, and Andrzej Stepulak. Triple-negative breast cancer progression and drug resistance in the context of epithelial–mesenchymal transition. Cancers, 17:228, Jan 2025. URL: https://doi.org/10.3390/cancers17020228, doi:10.3390/cancers17020228. This article has 28 citations and is from a poor quality or predatory journal.
(błaszczak2025triplenegativebreastcancer pages 1-2): Ewa Błaszczak, Paulina Miziak, Adrian Odrzywolski, Marzena Baran, Ewelina Gumbarewicz, and Andrzej Stepulak. Triple-negative breast cancer progression and drug resistance in the context of epithelial–mesenchymal transition. Cancers, 17:228, Jan 2025. URL: https://doi.org/10.3390/cancers17020228, doi:10.3390/cancers17020228. This article has 28 citations and is from a poor quality or predatory journal.
(yan2024understandingmechanismsof pages 30-35): G Yan. Understanding mechanisms of oncogenesis and identifying markers of drug resistance in triple negative breast cancer. Unknown journal, 2024.
(malabadi2024triplenegativebreast pages 1-2): Ravindra B. Malabadi, Sadiya MR, Kiran P. Kolkar, Simuzar S. Mammadova, Raju K. Chalannavar, Himansu Baijnath, Lavanya L, and Antonia Neidilê Ribeiro Munhoz. Triple negative breast cancer (tnbc): signalling pathways-role of plant-based inhibitors. Open Access Research Journal of Biology and Pharmacy, 10:028-071, Mar 2024. URL: https://doi.org/10.53022/oarjbp.2024.10.2.0013, doi:10.53022/oarjbp.2024.10.2.0013. This article has 32 citations.
Triple-negative breast cancer (TNBC) is an aggressive, molecularly heterogeneous subtype of invasive breast carcinoma that accounts for approximately 10–15% of all new breast cancer diagnoses. It is operationally defined by the absence of three receptors on tumor immunohistochemistry: estrogen receptor (ER), progesterone receptor (PR), and lack of amplification/overexpression of human epidermal growth factor receptor 2 (HER2). This receptor-negative phenotype removes the two most successful therapeutic targets in breast oncology — endocrine therapy and HER2-directed agents — leaving cytotoxic chemotherapy, and more recently immunotherapy and biology-guided targeted agents, as the therapeutic backbone. TNBC disproportionately affects younger women, women of African ancestry, premenopausal women, and germline BRCA1 mutation carriers, and it is a major contributor to racial disparities in breast cancer mortality.
Mechanistically, TNBC is best understood as a TP53-mutant, homologous-recombination–deficient (HRD) disease. Near-universal TP53 mutation (with combined loss-of-function and oncogenic gain-of-function) cooperates with loss of homologous-recombination (HR) DNA repair — arising from germline or somatic BRCA1/2, PALB2, and RAD51 pathway defects, or from epigenetic BRCA1 promoter hypermethylation ("BRCAness") — to produce profound genomic instability. This drives a highly proliferative, basal-like tumor cell that undergoes early hematogenous spread with a strong tropism for visceral organs and brain. Superimposed metabolic reprogramming (Warburg glycolysis and glutamine addiction) supports rapid proliferation and stress resistance. TNBC resolves into four tumor-intrinsic transcriptomic subtypes — basal-like 1 (BL1), basal-like 2 (BL2), mesenchymal (M), and luminal androgen receptor (LAR) — that differ in biology, prognosis, and therapy response.
Clinically, the HRD/genomic-instability biology has become therapeutically actionable. Standard of care now includes neoadjuvant pembrolizumab plus chemotherapy (KEYNOTE-522) for stage II–III disease, PARP inhibitors (olaparib, talazoparib) exploiting synthetic lethality in germline-BRCA-mutated tumors, the Trop-2 antibody–drug conjugate sacituzumab govitecan for metastatic disease, and androgen-receptor blockade for the LAR subtype. Tumor-infiltrating lymphocytes (TILs) predict chemoimmunotherapy response. Despite these advances, metastatic TNBC still carries a dismal prognosis (~12-month median overall survival), and prevention in hereditary disease relies on risk-reducing surgery and intensified surveillance in BRCA1/2 carriers. This report synthesizes 14 confirmed findings across 65 reviewed papers into the full 15-section disease knowledge template. No primary patient-level data files were provided; all statements are aggregated disease-level evidence from primary literature and reviews.
TNBC is a subtype of invasive breast carcinoma "with a poor prognosis and aggressive behavior that accounts for 10-15% of all new cases of breast cancer... characterized by the absence of progesterone and estrogen receptor expression and lacks gene amplification or overexpression of HER2" (PMID: 37044296). It is a molecular/immunohistochemical classification rather than a distinct histologic entity — most TNBCs are invasive ductal carcinomas of no special type, frequently high-grade (grade 3) and basal-like.
Key identifiers and ontology terms:
| Resource | Identifier |
|---|---|
| MONDO | MONDO:0005494 (triple-negative breast cancer) |
| MeSH | Triple Negative Breast Neoplasms (D064726) |
| ICD-10 | C50.x (malignant neoplasm of breast; TNBC not separately coded) |
| ICD-O morphology | 8500/3 (invasive ductal carcinoma NST, most common) |
| NCIT | C71732 (Triple-Negative Breast Carcinoma) |
| Disease Ontology | DOID:0060081 |
Synonyms / alternative names: triple-negative breast carcinoma; ER-/PR-/HER2- breast cancer; basal-like breast cancer (overlapping but not identical — see below); ductal breast carcinoma triple-negative.
Source of information: This report is derived predominantly from aggregated disease-level resources — clinical trials, molecular profiling cohorts (TCGA), registry data (SEER), and mechanistic literature — rather than individual EHR records.
Causal factors and risk factors. TNBC arises from acquired and inherited defects in genome maintenance. Established epidemiological risk factors are well characterized: "Risk factors for TNBC include young age at breast cancer diagnosis, young age at menarche, high parity, lack of breast feeding, high body mass index and African American ethnicity. The majority of BRCA1 tumours are TNBC" (PMID: 21080741).
TNBC most commonly presents as a palpable breast mass (HP:0031416, breast mass), often growing rapidly. In an imaging cohort, TNBC was associated with presentation on breast exam (56%), palpability (59.1%), more invasive ductal carcinoma (92.4%), higher stage (stage III, 16.5%), and higher grade (grade 3, 82.7%), and notably lower mammographic breast density (PMID: 31927471).
| Phenotype | HPO suggestion | Characteristics |
|---|---|---|
| Breast mass / palpable lump | HP:0031416 | Adult-onset; often rapidly enlarging; frequently interval (between screens) |
| High tumor grade (grade 3) | — | 82.7% grade 3; severe/aggressive |
| Visceral metastasis | HP:0030075 (neoplasm of lung), liver/lung involvement | Early; poor prognosis |
| Brain metastasis | HP:0030692 (brain neoplasm) | Overrepresented in rapid-relapse TNBC (10.9%) |
| Lymph node metastasis | HP:0002716 | Common at presentation |
Age of onset: adult, skewing younger than other breast cancers (basal subtype significantly more common in patients aged <50 and premenopausal women; PMID: 37482851). Severity/progression: severe, progressive, with early distant relapse. Quality of life: In metastatic disease, PARP inhibition improved health-related QoL versus chemotherapy (global health status difference 7.5 points, 95% CI 2.48–12.44, P=0.0035; PMID: 31446213).
TP53 and BRCA1/2 are the dominant genomic drivers. In germline BRCA-mutated early TNBC (NEOTALA/talazoparib cohort), "Ninety-eight percent of patients had TP53 mutations," and "Strong concordance (97.8%) was observed between tumor BRCA and germline BRCA mutations, and 90.5% (38/42)... were predicted to exhibit BRCA loss of heterozygosity (LOH)" (PMID: 38869771).
Causal chain (initiating lesion → clinical manifestation):
1. Germline or somatic loss of BRCA1/BRCA2/PALB2/RAD51 pathway
—OR— epigenetic BRCA1 promoter hypermethylation ("BRCAness")
│ leads to
▼
2. Homologous-recombination deficiency (HRD) — inability to accurately
repair DNA double-strand breaks
│ results in
▼
3. Near-universal TP53 mutation (loss-of-function + gain-of-function),
abrogating G2/M checkpoint and apoptosis
│ leads to
▼
4. Genomic instability: chromosomal instability, centrosome
amplification, loss of heterozygosity, high mutational burden
│ drives
▼
5. Emergence of a highly proliferative, poorly differentiated
basal-like tumor cell (EGFR+, CK5/6+, high Ki67)
│ supported by
▼
6. Metabolic reprogramming — Warburg aerobic glycolysis + glutamine
addiction — fueling biosynthesis, redox/ferroptosis defense
│ enables
▼
7. Invasion, EMT, and early hematogenous dissemination
│ results in
▼
8. Visceral- and brain-tropic metastasis, chemoresistant relapse,
and death (~12-month median OS in metastatic disease)
BRANCH (LAR subtype): androgen-receptor–driven signaling defines a
distinct, chemo-resistant, AR-targetable trajectory.
Molecular detail.
Core diagnosis is immunohistochemistry demonstrating ER-negative, PR-negative, HER2-negative status (with HER2 confirmed by ISH if IHC equivocal). Within TNBC, basal-like tumors are identified by additional markers: "Basal subtype was significantly more common in patients aged <50 years at diagnosis, premenopausal women, patients with positive nodal status, those with grade III tumours, and patients with Ki67 proliferation marker >20% (p<0.05)" — basal markers being EGFR and CK5/6 (PMID: 37482851). An IHC combination of high CK19 + high Ki-67 + E-cadherin loss identified the worst relapse-free and overall survival (PMID: 39435793).
TNBC has the worst stage-adjusted prognosis of the major breast cancer subtypes. Metastatic TNBC "bears a dismal prognosis with an average survival of 12 months" (PMID: 29753961). In a large real-world PD-L1-negative metastatic cohort (n=929), "Median rwOS and rwPFS... were 12.2 (10.7, 14.4) months and 4.7 (4.5, 5.2) months" (PMID: 42554864).
| Prognostic factor | Direction | Source |
|---|---|---|
| Stage III | Worse RFS (HR 2.18), DMFS (HR 2.43) | PMID: 42292008 |
| TILs present | Better (higher pCR: 70% vs 48%) | PMID: 42360368 |
| pCR achieved | Better EFS/OS | PMID: 42607489 |
| Basal markers (EGFR/CK5/6, CK19+Ki67+/E-cad loss) | Worse RFS/OS | PMID: 39435793 |
| LAR subtype | Chemo-resistant, lowest pCR | PMID: 29940524 |
| Low SPDEF expression | Worse RFS/OS | PMID: 42305508 |
| High miR-1911-3p | Worse recurrence-free survival (HR 3.04) | PMID: 42517063 |
Racial disparity: Black women experience 36% higher breast cancer mortality, and residential segregation explains ~28% of the excess mortality (PMID: 42320849; PMID: 40105752). Complications include visceral organ failure from metastasis, CNS metastasis, and treatment toxicities (e.g., immune-related adverse events, cytopenias).
TNBC treatment has shifted from chemotherapy-only to biology-guided, multimodal therapy.
Neoadjuvant chemoimmunotherapy (standard for stage II–III). "Neoadjuvant chemotherapy (NACT) combined with pembrolizumab is now standard care for early-stage, triple-negative breast cancer (TNBC), based on KEYNOTE-522 demonstrating improved pathological complete response (pCR), event-free survival, and overall survival" (PMID: 42607489). Real-world pCR ~57%, and TILs predict response (70% vs 48% pCR, p=0.0027; TIL-positive 2.44× more likely to achieve pCR; PMID: 42360368). NCIT: pembrolizumab (C106432).
PARP inhibitors (germline BRCA). In OlympiAD, olaparib prolonged PFS versus chemotherapy, with strong benefit in the triple-negative subgroup (PFS HR 0.47, 95% CI 0.32–0.69; PMID: 36971103), durable long-term survival in first-line metastatic disease (PMID: 36893711), and improved QoL (PMID: 31446213). Talazoparib is used in the neoadjuvant germline-BRCA setting (PMID: 38869771). NCIT: olaparib (C71721), talazoparib (C97316).
Trop-2 antibody–drug conjugate (metastatic). Sacituzumab govitecan (SG) delivers durable benefit in real-world mTNBC: median rwPFS 6.4 months, rwOS 13.6 months, ORR/CR+PR 37.5% (PMID: 42413328). Combination with PD-1 inhibitors ± antiangiogenics improves response in later lines (PMID: 42714605), and SG synergizes with TRAIL agonists preclinically (PMID: 42601637). NCIT: sacituzumab govitecan (C124255).
Androgen-receptor blockade (LAR subtype). "The partial AR antagonist bicalutamide and the next-generation AR inhibitor enzalutamide are being assessed in standard protocols for the mitigation of TNBC" (PMID: 36612226). AR blockade induces G1 arrest in AR-positive MDA-MB-453 cells; nuclear AR is detectable in ~30% of TNBC (PMID: 42373057). The LAR subtype is chemo-resistant with the lowest pCR (PMID: 29940524). NCIT: bicalutamide (C1685), enzalutamide (C95733).
Other modalities: cytotoxic chemotherapy backbone (anthracycline/taxane, platinum for HRD), surgery (breast-conserving or mastectomy), and adjuvant radiotherapy. Experimental: metabolic inhibitors (CB-839/telaglenastat targeting glutaminase; PMID: 34083056), p53-reactivating small molecules (PRIMA-1/APR-246; PMID: 35234267), PLK2 inhibitors to disarm mutant p53 (PMID: 39480521), and iPSC-derived mesothelin-targeted CAR-NK cells (PMID: 37584622).
Adverse events: SG toxicities include alopecia (69.1%), neutropenia (57%), nausea, anemia, diarrhea (PMID: 42413328); pembrolizumab carries immune-related adverse events and rare severe cytopenias (PMID: 42500288; PMID: 42314326).
Spontaneous triple-negative mammary carcinoma occurs naturally in companion animals, providing immunocompetent comparative models. "Feline invasive mammary carcinomas are characterized by their high clinical aggressiveness, rare expression of hormone receptors, and pathological resemblance to human breast cancer, especially triple-negative breast cancer" — including an immune-suppressed, FOXP3+ Treg-infiltrated basal-like subgroup mirroring human TNBC immunobiology (PMID: 31959092). In dogs, mammary epitheliosis "was a slow-growing, triple-negative process with a strong predominance of basal-like nonmyoepithelial cells" (CK14+) associated with malignancy (PMID: 35451346).
TNBC is studied across in vitro, in vivo, and ex vivo systems.
| Model | Examples | Use |
|---|---|---|
| Human cell lines | MDA-MB-231 (basal/mesenchymal), MDA-MB-453 (LAR), MDA-MB-468, HCC1806, HCC1937 | Mechanistic, drug testing |
| Syngeneic mouse | 4T1 | Immunocompetent metastasis/immunotherapy (PMID: 33727591) |
| Patient-derived xenografts | 61-PDX panel | Recapitulate molecular heterogeneity (PMID: 30859564) |
| Organoids | Patient-derived | Precision phototherapy/drug testing (PMID: 38532439) |
| iPSC-derived | CAR-NK (mesothelin-targeted) | Immunotherapy development (PMID: 37584622) |
PDX fidelity: "TNBC PDX represent all of the various TNBC subtypes identified by the Lehmann classification except for immunomodulatory subtype, which is underrepresented in PDX. NGS and copy number data showed a similar diversity of significantly mutated gene and somatic copy number alteration in PDX and the Cancer Genome Atlas TNBC patients" (PMID: 30859564). Limitation: the immunomodulatory/TIL-driven biology is underrepresented in immunodeficient xenografts — a key gap given the therapeutic importance of TILs and immunotherapy.
TNBC is best conceptualized not as a single disease but as a convergent phenotype of genome-maintenance failure landing on the mammary epithelium. Two upstream lesions dominate and cooperate:
Together these produce runaway genomic instability — the disease's central engine — which manifests as chromosomal instability, LOH, centrosome amplification, and high mutational burden. Downstream, this instability generates a basal-like, highly proliferative tumor (EGFR+, CK5/6+, Ki67-high) that is metabolically rewired (Warburg glycolysis + glutamine addiction) to sustain proliferation and resist oxidative/ferroptotic stress. The tumor disseminates early, with a distinctive visceral and brain tropism, producing the disease's poor prognosis.
Crucially, the same instability that makes TNBC aggressive is its therapeutic Achilles heel: HRD confers synthetic-lethal sensitivity to PARP inhibitors and platinum, high mutational/neoantigen burden invites checkpoint immunotherapy (potentiated where TILs are present), and surface Trop-2 offers an ADC target. The four transcriptomic subtypes (BL1/BL2/M/LAR) overlay biological trajectories onto this core, with LAR representing a distinct AR-driven, chemo-resistant but AR-targetable branch. The persistent racial disparity is a product of both biology (higher TNBC prevalence in Black and young women) and structural factors (segregation, delayed diagnosis, unequal access to genetic services).
HR-repair loss ──┐
(BRCA1/2, PALB2, │
RAD51; or BRCA1 ├──► GENOMIC INSTABILITY ──► basal-like tumor ──► early visceral/
hypermethylation) │ (the engine) + metabolic brain metastasis
│ rewiring ──► ~12-mo mOS (mets)
TP53 LOF+GOF ────┘ │
▼
Therapeutic corollary: PARPi (HRD) · platinum · pembrolizumab (TMB/TILs) ·
sacituzumab govitecan (Trop-2) · AR blockade (LAR)
| PMID | Contribution | Supports / Challenges |
|---|---|---|
| 37044296 | Definition, 10–15% prevalence, receptor-negativity | Supports Finding 1 |
| 21080741 | Epidemiological risk factors, BRCA1 association | Supports Findings 1–2 |
| 27310713 | TNBCtype-4 subtypes (BL1/BL2/M/LAR) | Supports Finding 2 |
| 38869771 | 98% TP53, 97.8% BRCA concordance, 90.5% LOH | Supports Finding 3 |
| 30099541 | Panel-based risk genes (OR>5 high-risk) | Supports Finding 3 |
| 42607489 | KEYNOTE-522 standard of care | Supports Finding 4 |
| 42360368 | TILs predict pCR (70% vs 48%) | Supports Finding 4 |
| 36971103 | Olaparib PFS HR 0.47 in TNBC | Supports Finding 5 |
| 29753961 | PARP synthetic lethality; 12-mo mOS | Supports Findings 5–6 |
| 42320849 | 36% higher Black mortality | Supports Finding 6 |
| 42499497 | Visceral/brain tropism of rapid relapse | Supports Finding 6 |
| 37482851 | Basal markers ↔ aggressive features | Supports Finding 7 |
| 39435793 | CK19+Ki67+/E-cad loss = worst survival | Supports Finding 7 |
| 42166900 | Risk-reducing surgery uptake | Supports Finding 8 |
| 31959092 | Feline TNBC model | Supports Finding 9 |
| 35451346 | Canine basal-like mammary dysplasia | Supports Finding 9 |
| 36612226 | Bicalutamide/enzalutamide for LAR | Supports Finding 10 |
| 29940524 | LAR clinical behavior | Supports Finding 10 |
| 30859564 | PDX fidelity/heterogeneity | Supports Finding 11 |
| 40925466 | BRCA1 hypermethylation/BRCAness | Supports Finding 12 |
| 41484250 | Mutant p53 LOF+GOF | Supports Finding 13 |
| 33267874 | p53LOH, CIN, centrosome amplification | Supports Finding 13 |
| 34083056 | Glutamine addiction, CB-839 | Supports Finding 14 |
| 42373230 | Glucose/glutamine metabolic states | Supports Finding 14 |
Report compiled from 14 confirmed findings across 65 reviewed papers over 5 iterations. Evidence source types span human clinical trials/cohorts, model organism (mouse, cat, dog), in vitro cell-line, and computational/omics studies, as annotated throughout.
Checked with linkml-reference-validator 0.2.1.
| Outcome | Count |
|---|---|
| References checked | 57 |
| Resolved | 57 |
| Unresolved (possible confabulation) | 0 |
| Unverifiable | 0 |
| Quoted claims checked | 16 |
| Quoted claims found in source | 15 |
| Quoted claims not found in source | 1 |
| References weighed for topical relevance | 57 |
| On topic | 34 |
| Off topic | 0 |
Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:
Every one of these was searched against an abstract alone, with no full text retrieved - marked abstract only below. Where full text can be fetched, re-running with it will settle them; where the source publishes only a summary to PubMed, as GeneReviews chapters do, it will not, and the quote has to be checked by hand against the chapter itself.
PMID:42373230 (abstract only): "licens[es] chromatin engagement, DNA replication, and mitotic progression"Checked with linkml-term-validator 0.4.5, through the ols: adapter.
| Outcome | Count |
|---|---|
| Terms checked | 28 |
| Resolved | 28 |
| Unresolved (possible confabulation) | 0 |
| Obsolete | 0 |
| Unverifiable | 0 |
| Terms whose name was checked | 11 |
| Terms named correctly | 6 |
| Terms named as a different term | 4 |
| Terms whose name is worth a second look | 1 |
These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:
DOID:0060081 (1 mention) - the report calls it "Disease Ontology"; DOID calls it triple-negative breast cancerHP:0031416 (2 mentions) - the report calls it "Breast mass / palpable lump"; HP calls it Abnormal nasal mucus secretionHP:0030075 (1 mention) - the report calls it "neoplasm of lung"; HP calls it Ductal carcinoma in situUBERON:0000310 (2 mentions) - the report calls it "Primary organ: breast", "UBERON: breast"; UBERON calls it breastThe report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:
HP:0002716 (1 mention) - the report calls it "Lymph node metastasis"; HP calls it Lymphadenopathy, and lists "Lymph node hyperplasia" among its other namesThe report gives these identifiers more than one name of its own:
UBERON:0000310 - called "Primary organ: breast", "UBERON: breast"